by Lupus Foundation, Ohio | Jan 9, 2026 | Lupus Foundation of America, News & Events
Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug therapy, nipocalimab, met its primary endpoint and multiple key secondary and exploratory endpoints in adults with systemic lupus...
by | Dec 18, 2025 | Lupus Foundation of America, News & Events
A new study finds that experiences of discrimination are associated with worse patient-reported lupus-related symptoms and depressive symptoms among people with systemic lupus erythematosus (SLE). Patient-reported disease activity such as pain, fatigue and depression...
by | Dec 16, 2025 | Lupus Foundation of America, News & Events
In a new study, researchers have discovered a connection between inflammation in the areas of interstitial fibrosis and tubular atrophy (IFTA), a common pattern of kidney damage often seen in kidney disease, and renal outcomes. The researchers found that inflammation...
by | Nov 20, 2025 | Lupus Foundation of America, News & Events
A new groundbreaking study has recently identified the link between the long-standing mystery in autoimmune disease: Epstein-Barr Virus (EBV) and how it contributes towards the development of systemic lupus erythematosus (SLE). The study found that EBV infects a small...
by | Oct 26, 2025 | Lupus Foundation of America, News & Events
Today at the American College of Rheumatology (ACR) Annual Meeting, Convergence 2025, the ACR held a discussion of the new guidelines for the treatment and management of systemic lupus erythematosus (SLE), the most common form of lupus. These guidelines provide an...
by | Oct 9, 2025 | Lupus Foundation of America, News & Events
A new study has found that women with systemic lupus erythematosus who have problems with memory and thinking (mild cognitive impairment, or MCI) exhibit morphological brain changes, which may serve as potential biomarkers for early detection and monitoring. SLE...
